Clay Siegall is renowned for his targeted cancer therapies. He serves as the CEO and founder of Seattle Genetics. The Seattle-based company focuses on developing targeted therapy drugs for different diseases, especially cancer.
Since founding the company in 1998, he has provided transformative leadership, which has enhanced the growth of the corporation. The company is credited for creating the first anti-body drug conjugate that was approved by the FDA. Presently, Seattle Genetics is developing over 20 drugs. The corporation has entered into multiple strategic partnerships with different drug makers like Pfizer, Genentech, and Bayer.
Through Clay’s leadership, the small startup, with a few researchers, has grown to become a powerhouse in cancer research. Notably, Dr. Siegall has huge plans for Seattle Genetics. The company has continued to undertake comprehensive research with the objective of developing viable drugs. For this reason, the company is well-positioned to be an authority in the drug development industry in the 21st century.
According to Dr. Siegall, conformist cancer treatments, including systematic chemotherapies will soon be thrown in the historic dustbin. He believes that old systems will be displaced by the targeted therapies, which are tolerable and more effective.
Siegall notes that his love for research and entrepreneurship was driven by his interest in medicine, passion of developing therapies for different disease, and the power of technology. He always had a passion of restoring the health of those who would otherwise be consigned to death by fate. Dr. Siegall’s interest in the field of cancer treatment started when he was a student at the University of Maryland. Notably, Clay lost his father to cancer. Clay’s father had to undergo different treatments, all of which were painful. This experience contributed to Clay’s interest in developing cancer therapies.
About Clay Siegall
Clay Siegall is the chairman of Seattle Genetics. Dr. Siegall graduated with a B.S. in zoology from the University of Maryland. He also holds a PhD in genetics from George Washington University. Dr. Siegall has led the firm’s capital raising activities. To date, he has secured over $675 million through financing.
Previously, Dr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute. He has also rendered his services for the National Cancer Institute. Additionally, Dr. Siegall has written over 70 publications.